Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化
基本信息
- 批准号:7664259
- 负责人:
- 金额:$ 45.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-01 至 2011-07-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAcetatesAmino AcidsAnabolismAntibiotic A23187Arachidonic AcidsBe++ elementBerylliumBiochemicalBiologyBolus InfusionBradykininCatalysisCell CycleCell Differentiation processCellsCommitCoxibsCultured CellsCysteineCytosolic Phospholipase A2DietDinoprostoneDocosahexaenoic AcidsEMSAEicosapentaenoic AcidEicosatetraenoic AcidsElectrophoretic Mobility Shift AssayElementsEmbryoEndoglycosidasesEngineeringEnvironmentEstersEventFatty AcidsFibroblastsFish OilsFlurbiprofenGenesGlycerophospholipidsGoalsHealth BenefitHousekeepingHumanHydrogen PeroxideIn VitroIonophoresKidneyKineticsKnock-in MouseKnockout MiceLearningLinoleic AcidsMammalian CellMeasuresMusNIH 3T3 CellsNon-Steroidal Anti-Inflammatory AgentsOmega-6 Fatty AcidsOutcome StudyPPIXPTGS1 genePTGS2 genePathway interactionsPenicillinsPeroxidasesPhasePhenotypePhospholipidsPlatelet-Derived Growth FactorPropertyProstaglandin EndoperoxidesProstaglandin-Endoperoxide SynthaseProstaglandinsProtein IsoformsProtoporphyrinsReduced GlutathioneRegulationResearchResearch PersonnelRoleSeriesStimulusStreptomycinSystemTestingThromboxane ReceptorThromboxanesTimecyclooxygenase 1designfeedingimmunocytochemistryin vivokifunensinemead acidmouse PGE synthase 1overexpressionphorbol-12-myristateprogesterone 11-hemisuccinate-(2-iodohistamine)programsprostaglandin R2 D-isomeraseprotein degradationresearch studyurinary
项目摘要
DESCRIPTION (provided by applicant): The long-term goal of our studies is to understand how prostaglandin (PG) synthesis is regulated. There are two PGH synthases (PGHS-1 and -2) each able to catalyze the committed step in PG formation-oxygenation of the omega 6 fatty acid arachidonic acid (AA) or the co3 fatty acid eicosapentaenoic acid. PGHSs, also known as cyclooxygenases (COXs), are products of different genes; typically, PGHS-1 is expressed constitutively, while PGHS-2 is expressed transiently. Each PGHS isoform subserves different biologies, and a central question is how this can occur. PGHS-1 displays negative substrate cooperativity. We posit that this restricts PGHS-1 to operating only at high AA concentrations when a bolus of PGs is required for a pulsatile, housekeeping event-something that could happen at any time during the cell cycle. Unlike PGHS-1, PGHS-2 can function at all substrate concentrations. We suggest that its normal function is to provide a slow, continuous synthesis of PGs during a 1-2 h period preceding cell differentiation or replication when AA levels are low and PGHS-2 is briefly present. In short, we hypothesize that regulation of PGHS-1 activity is kinetic while control of PGHS-2 activity resides in its expression. These ideas can explain how when the isoforms are co-expressed in cells, PGHS-2 can be active while PGHS-1 is latent. The kinetic properties of PGHS-1 permit its functioning in vitro only when AA or EPA levels reach > 1-2 uM. It is probably rare that cellular EPA levels become this high; moreover, EPA is a very poor substrate for PGHS-1. So we suggest that except at unusually high EPA/AA ratios, EPA does not function as a substrate for PGHS-1 in vivo. Some beneficial effects of dietary fish oil could relate to the inactivity of PGHS-1 with EPA. Specific Aim #1 will test our concepts about the differences in the abilities of PGHS-1 and PGHS-2 to oxygenate low vs. high concentrations of endogenous AA vs. EPA in cells. Fibroblasts expressing PGHS-1 or PGHS-2 and having different EPA/AA ratios in their phospholipids will be cultured. PGE2 and PGEj, synthesis will be measured with cells stimulated to mobilize low vs. high levels of endogenous substrates. To determine if PGHS-1 can oxygenate EPA in vivo, PGHS-2 null mice will be fed fish oil and urinary, EPA-derived PGs will be quantified. Specific Aim #2 will examine an unexplored aspect of the control of PGHS-2 expression-protein degradation. Compared to PGHS-1 degradation, PGHS-2 degradation is rapid (tj/2 ~ 2 h). We have identified a 27 amino acid instability element (27-IE) near the C-terminus of PGHS-2 that targets it to the ER-associated degradation system. We will define structural features of the 27-IE involved in its function and will phenotype a newly engineered PGHS-2 knock-in mouse having a non-functional 27-IE.
描述(由申请人提供):我们研究的长期目标是了解前列腺素(PG)如何调节合成。有两个PGH合酶(PGHS-1和-2)能够催化Omega 6脂肪酸(AA)或CO3脂肪酸eicosapentaenoic的PG形成 - 氧化中的成分步骤。 PGHSS,也称为环氧酶(Coxs),是不同基因的产物。通常,PGHS-1组成型表达,而PGHS-2则瞬时表达。每个PGHS同工型都会产生不同的生物,一个核心问题是如何发生这种情况。 PGHS-1显示负底物协作。我们认为,这限制了PGHS-1仅在高度AA浓度下运行时,当PGS的大麻需要在细胞周期期间任何时候发生的脉冲,家政事件可能发生。与PGHS-1不同,PGHS-2可以在所有底物浓度下起作用。我们建议它的正常功能是在细胞分化或复制之前的1-2小时内提供缓慢,连续的PG合成,而当AA水平较低并且PGHS-2短暂存在时。简而言之,我们假设PGHS-1活性的调节是动力学的,而对PGHS-2活性的控制则存在于其表达中。这些想法可以解释何时在细胞中共表达同工型时,PGHS-2可以在PGHS-1潜在时活跃。 PGHS-1的动力学特性仅在AA或EPA水平> 1-2 um时才能在体外功能。细胞EPA水平变得如此高可能很少。此外,EPA对于PGHS-1来说是非常差的底物。因此,我们建议,除了异常高的EPA/AA比,EPA在体内的底物不起作用。膳食鱼油的一些有益作用可能与EPA与PGHS-1的不活跃有关。特定的目标#1将测试我们关于PGHS-1和PGHS-2在细胞中氧化低和高浓度的内源性AA与EPA的氧合能力差异的概念。将培养表达PGHS-1或PGHS-2并在其磷脂中具有不同EPA/AA比的成纤维细胞进行培养。 PGE2和PGEJ,将用刺激的细胞来测量合成,以动员低水平的内源性底物。为了确定PGHS-1是否可以在体内充氧EPA,PGHS-2无效小鼠将被喂食鱼油和尿液,将量化EPA衍生的PG。特定的目标#2将检查PGHS-2表达蛋白降解的控制的未开发方面。与PGHS-1降解相比,PGHS-2降解是快速的(TJ/2〜2 h)。我们已经在PGHS-2的C端附近确定了一个27个氨基酸不稳定性元件(27-IE),该氨基酸元素将其靶向与ER相关的降解系统。我们将定义与其功能相关的27-IE的结构特征,并将表型具有非功能性27-IE的新设计的PGHS-2敲入小鼠。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William L Smith其他文献
William L Smith的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William L Smith', 18)}}的其他基金
Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化作用
- 批准号:
7932688 - 财政年份:2009
- 资助金额:
$ 45.34万 - 项目类别:
Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化作用
- 批准号:
7109363 - 财政年份:2003
- 资助金额:
$ 45.34万 - 项目类别:
Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化
- 批准号:
6936502 - 财政年份:2003
- 资助金额:
$ 45.34万 - 项目类别:
Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化
- 批准号:
7317189 - 财政年份:2003
- 资助金额:
$ 45.34万 - 项目类别:
Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化
- 批准号:
6677554 - 财政年份:2003
- 资助金额:
$ 45.34万 - 项目类别:
Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化
- 批准号:
8185845 - 财政年份:2003
- 资助金额:
$ 45.34万 - 项目类别:
Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化作用
- 批准号:
8658102 - 财政年份:2003
- 资助金额:
$ 45.34万 - 项目类别:
Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化
- 批准号:
8323415 - 财政年份:2003
- 资助金额:
$ 45.34万 - 项目类别:
Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化作用
- 批准号:
8469864 - 财政年份:2003
- 资助金额:
$ 45.34万 - 项目类别:
Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化
- 批准号:
6792121 - 财政年份:2003
- 资助金额:
$ 45.34万 - 项目类别:
相似国自然基金
微囊泡介导肺泡上皮祖细胞醋酸盐代谢重编程向AT2细胞分化促进ARDS炎症修复的作用机制
- 批准号:82360020
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
肝癌微环境富集醋酸盐增强内皮细胞乙酰化修饰并促进血管生成
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
肝癌微环境富集醋酸盐增强内皮细胞乙酰化修饰并促进血管生成
- 批准号:82273313
- 批准年份:2022
- 资助金额:52.00 万元
- 项目类别:面上项目
络合萃取法提取生物油酚类化合物的效能及机理研究
- 批准号:21206142
- 批准年份:2012
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
CANAVAN DISEASE: SUPPRESSING THE PHENOTYPE BY INHIBITING NAA SYNTHESIS
CANAVAN 病:通过抑制 NAA 合成来抑制表型
- 批准号:
8965565 - 财政年份:2015
- 资助金额:
$ 45.34万 - 项目类别:
Catalysis by Prostaglandin Endoperoxide H Synthases
前列腺素内过氧化物 H 合成酶的催化作用
- 批准号:
7932688 - 财政年份:2009
- 资助金额:
$ 45.34万 - 项目类别:
DOUBLE-TARGETED MACROMOLECULAR THERAPEUTICS FOR THE TREATMENT OF PROSTATE CANCER
治疗前列腺癌的双靶点大分子疗法
- 批准号:
8197950 - 财政年份:2008
- 资助金额:
$ 45.34万 - 项目类别:
DOUBLE-TARGETED MACROMOLECULAR THERAPEUTICS FOR THE TREATMENT OF PROSTATE CANCER
治疗前列腺癌的双靶点大分子疗法
- 批准号:
8019008 - 财政年份:2008
- 资助金额:
$ 45.34万 - 项目类别:
DOUBLE-TARGETED MACROMOLECULAR THERAPEUTICS FOR THE TREATMENT OF PROSTATE CANCER
治疗前列腺癌的双靶点大分子疗法
- 批准号:
7582316 - 财政年份:2008
- 资助金额:
$ 45.34万 - 项目类别: